Experts Discuss Sequencing of Therapies for Relapsed/Refractory Multiple Myeloma

In relapsed/refractory multiple myeloma, prior therapy can affect subsequent treatment efficacy, highlighting the importance of thoughtful sequencing and consideration of alternative targets. Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates, bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.